Table 3.

Cox multivariate analysis of TAM and TAN densities, and other pathological features predicting the outcome of stage III colorectal cancer treated with 5-fluorouracil adjuvant therapy^a

	Biomarker (High vs. Low)		Nodal Status (N2 vs. N1)		Vascular Invasion (Y vs. N)
	HR (95% CI)	p	HR (95%CI)	p	HR (95%CI)	p
A. Disease-Free Survival in the Institutional Cohort
by PT-TAMsb	0.23 (0.08–0.65)	0.005	2.43 (1.34–4.42)	0.001	2.02 (1.11–3.68)	0.02
by LN-TAMsb	0.13 (0.04–0.43)	0.001	2.35 (1.19–4.63)	0.01	2.36 (1.21–4.62)	0.01
by TANsc	0.53 (0.22–1.30)	0.17	2.47 (1.31–4.67)	0.005	2.29 (1.22–4.30)	0.01
B. Disease-Specific Survival in the External Validation Set
by PT-TAMsb	0.14 (0.02–1.00)	0.05	2.54 (1.09–5.90)	0.03	1.57 (0.58–4.21)	0.37

^aDistinct models were constructed to weight the predictive value of each candidate biomarker. Only variables with a p value less than 0.10 at univariate analysis (see Table 3) were entered.

^bpercent CD68-immunoreactive area (IRA) at the invasive front of the primary tumor (PT-TAMs) or of metastatic lymph nodes (LN-TAMs). Low vs. high densities are defined by optimal cut-offs from Receiver Operator Characteristic curves (8.0% IRA for PT-TAMS and 3.7% IRA for LN-TAMs)

^cpercent CD66b-immunoreactive (IRA) within the primary tumor (TANs). Low vs. high densities are defined by optimal cut-offs from Receiver Operator Characteristic curves (1.16% IRA )